Previous 10 | Next 10 |
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study - Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to pl...
Incyte (INCY) and MorphoSys AG (MOR) announce that the first patient has been dosed in a late-stage testing tafasitamab combo in patients with a form of lymphoma.The placebo-controlled Phase 3 inMIND study evaluates the efficacy and safety of tafasitamab or placebo in combination with le...
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with le...
Eli Lilly (LLY) and Incyte (INCY) announced that their baricitinib treatment failed to meet the main goal in a late-stage trial testing the drug in hospitalized patients with COVID-19.The trial did not meet statistical significance on the primary endpoint, which was defined as a differen...
A better understanding is needed of the financial implications for Incyte with its major product, Jakafi, facing LOE in 2027. Analysis indicates there's considerable uncertainty among analysts as to Incyte's future earnings capabilities. Despite the risks, due to uncertainty, the ...
In January, when Merck ([[MRK]] +0.4%) announced its plans to abandon the development of two potential COVID-19 vaccines, the company reaffirmed its commitment to MK-7110 and MK-4482 (molnupiravir), two investigational coronavirus therapies.As vaccine rollout gains momentum despite extre...
The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte Corporation (INCY) Presents at AACR Virtual Meeting 2021 - Slideshow
High-Volume Penny Stocks to Watch Right Now As another week in April comes to an end, what are the best penny stocks to watch right now? While this is not a simple question by any means, there are some solid examples of penny stocks that could be worth a closer look. This is due to a co...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...
The FDA feedback on an upcoming regulatory review and differing opinions on commercialization prospects of key therapies are some of the reasons for analysts to change their outlook on stocks today. Provention Bio sinks further as RBC downgrades it on FDA feedbackProvention Bio (PRVB) ha...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...